Wed, April 27, 2022
Tue, April 26, 2022
Mon, April 25, 2022
Sun, April 24, 2022
Fri, April 22, 2022
Thu, April 21, 2022

Matthew Harrison Downgraded (ALNY) to Hold and Decreased Target to $178 on, Apr 25th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. nd-decreased-target-to-178-on-apr-25th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Downgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Hold and Decreased Target from $210 to $178 on, Apr 25th, 2022.

Matthew has made no other calls on ALNY in the last 4 months.



There are 5 other peers that have a rating on ALNY. Out of the 5 peers that are also analyzing ALNY, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $103 on, Friday, February 11th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $400 on, Tuesday, April 12th, 2022
  • David Lebowitz of "Citigroup" Initiated at Strong Buy and Held Target at $223 on, Tuesday, March 1st, 2022
  • Etzer Darout of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $170 on, Thursday, February 3rd, 2022
  • Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022

Publication Contributing Sources